However, two other IL-1 blocking agents have been studied as therapy for sJIA, canakinumab (a monoclonal antibody to IL-1β) (8) and rilonacept (an IL-1 receptor fusion protein) (22). This evidence concerns the gene IL1B and systemic-onset juvenile idiopathic arthritis.